

### TIPS AND TRICKS FOR BETTER TOLERABILITY OF INTRAVESICAL GEMCITABINE/DOCETAXEL THERAPY


Version 1.2, Feb 16, 2024



MICHAEL A. O'DONNELL, MOHAMAD ABOU CHAKRA UNIVERSITY OF IOWA HOSPITALS AND CLINICS

IA, US

#### Intravesical Gem/Doce: Toxicity and Treatment




**Cancer (NMIBC)** 

impairment



# A. Pre-Treatment Recommendations



# **B. During Treatment Modifications**




A proper timer should be set for the appropriate dwell time. Additional time during drug instillation may increase side effects. A proper history before each instillation session allows the clinician to decide which technique should be used to administer the drugs, i.e., when bladder spasm occurs frequently, the gravity/reflux technique is preferable.

For patients who have had no difficulty holding the first medication, the catheter may be removed 5-10 minutes after the second drug is administered with instructions to void 60-90 minutes later.

Patients who cannot hold the second medication should be kept in the clinic supine until the dwell time is completed and then drained by gravity.

# C. Post Treatment Recommendations



# Expected side effects of Gem/Doce

	Urinary frequency (%)	Urgency (%)	Dysuria (%)	Hematuria (%)	UTI (%)	Nausea (%)	Asthenia (%)	Rash (%)	Grade III AE (%)	Adverse events affecting treatment schedule
Weighted Mean Results [8]	22%	21.6%	14%	9.6%	8.8%	7.5%	6.4%	6%	1%	9.1%

#### Better tolerability ensures better efficacy

- At least five of the six induction doses should be given for adequate therapy.
- Maintenance therapy of monthly instillations for 24 months is recommended if no recurrence occurs after completing induction.

#### **Appendix**





Figure 1Intravesical Gem/Doce instillation through a closed system.



1-Abou Chakra M, Packiam VT, O'Donnell MA. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer. Expert Opin Pharmacother. 2023:1-11.

2-McElree IM, Steinberg RL, Mott SL, et al. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. JAMA Netw Open. 2023 Feb 1;6(2):e230849.

3-Kahokehr A, Vather R, Nixon A, et al. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013 Feb;111(2):304-11.

4- Evans RJ. Intravesical therapy for overactive bladder. Curr Urol Rep. 2005 Nov;6(6):429-33.

5-Sun K, Wang D, Wu G, et al. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer Med. 2021 Nov;10(21):7534-7541.

6-Bogunovic OJ, Greenfield SF. Practical geriatrics: Use of benzodiazepines among elderly patients. Psychiatr Serv. 2004 Mar;55(3):233-5.

7- McElree IM, Mott SL, O'Donnell MA, et al. Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer. BJU International. Published online October 26, 2023.

8- Abou Chakra M, Packiam VT, Duquesne I, et al. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Expert Opin Pharmacother. 2024 Jan 24:1-12.